Loading patent…
AssigneePharma Mar, S.A.
InventorsVictoria Moneo Ocaña, Gema Santamaría Núñez, Luis Francisco García Fernández, Carlos María Galmarini, María José Guillén Navarro, Pablo Manuel Avilés Marín
Estimating the term…
The present invention relates to the combination of PM01183 with several anticancer drugs, in particular other anticancer drugs selected from antitumor platinum coordination complexes, antimetabolites, mitotic inhibitors, anticancer antibiotics, topoisomerase I and/or II inhibitors, proteasome inhibitors, histone deacetylase inhibitors, nitrogen mustard alkylating agents, nitrosourea alkylating agents, nonclassical alkylating agents, estrogen antagonists, androgen antagonists, mTOR inhibitors, tyrosine kinase inhibitors, and other agents selected from aplidine, ET-743, PM02734 and PM00104, and the use of these combinations in the treatment of cancer.
A method of treating cancer comprising administering to a patient in need of such treatment an amount of PM01183, or a pharmaceutically acceptable salt thereof, with an amount of
A method of inhibiting cancer cell growth comprising contacting cancer cells with PM01183, or a pharmaceutically acceptable salt thereof, in synergistic combination with irinotecan, wherein the cancer cells are lung cancer cells.
A method of increasing or potentiating the therapeutic efficacy of PM01183 monotherapy in the treatment of lung cancer, which comprises administering to a patient in need thereof a therapeutically effective amount of PM01183, or a pharmaceutically acceptable salt thereof, in conjunction with irinotecan.
Dependencies are inferred from the claim text.